New hope for Hard-to-Treat prostate cancer? early trial launches

NCT ID NCT07332455

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the first time this drug is being tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK5471713
What this could lead to: If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is an early first-in-human trial with only 54 participants, so safety and effectiveness are not yet established. Many experimental drugs fail to show benefit in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS PROSTATE

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

La Jolla, California, 92093, United States
GSK Investigational Site
RECRUITING

Grand Rapids, Michigan, 49546, United States
GSK Investigational Site
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
GSK Investigational Site
RECRUITING

West Valley City, Utah, 84119, United States
GSK Investigational Site
RECRUITING

Melbourne, Victoria, 3000, Australia
GSK Investigational Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site
RECRUITING

Tokyo, 104-0045, Japan
GSK Investigational Site
RECRUITING

Tokyo, 135-8550, Japan
GSK Investigational Site
RECRUITING

Seoul, Seoul Teugbyeolsi, 06351, South Korea
GSK Investigational Site
RECRUITING

Seoul, 120-752, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.